HIGHLIGHTS
- who: Chenglu Hu and collaborators from the School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China have published the article: PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC, in the Journal: Computational and Mathematical Methods in Medicine of 20/09/2022
- what: The main reasons for the poor prognosis include the limited effectiveness of chemo- therapy and radiotherapy treatment .
- how: The authors explored the expression and prognostic value of PLK4 in ccRCC and miRNAs acting on PLK4 followed by DNA methylation analysis. To further . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.